Carl LeBel - Frequency Therapeutics Chief Officer
Insider
Carl LeBel is Chief Officer of Frequency Therapeutics
| Age | 64 |
| Phone | 781 315-4600 |
| Web | www.frequencytx.com |
Frequency Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.425) % which means that it has lost $0.425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9993) %, meaning that it created substantial loss on money invested by shareholders. Frequency Therapeutics' management efficiency ratios could be used to measure how well Frequency Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Frequency Therapeutics currently holds 42.95 M in liabilities with Debt to Equity (D/E) ratio of 0.47, which is about average as compared to similar companies. Frequency Therapeutics has a current ratio of 6.63, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Frequency Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Andrew Hirsch | C4 Therapeutics | 53 | |
| Jonathan MS | Absci Corp | N/A | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Arnold Levine | Pmv Pharmaceuticals | 85 | |
| MD MBA | MAIA Biotechnology | 55 | |
| CPA CPA | Absci Corp | 65 | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Neelesh MD | Prelude Therapeutics | N/A | |
| Jack Gold | Absci Corp | N/A | |
| Casi DeYoung | Shattuck Labs | 54 | |
| Nancy Pecota | Adverum Biotechnologies | 64 | |
| Caryn Parlavecchio | Scholar Rock Holding | 53 | |
| Cyrus Harmon | Olema Pharmaceuticals | 53 | |
| Andreas Busch | Absci Corp | 62 | |
| Ioana Hone | Lineage Cell Therapeutics | N/A | |
| Noreen MD | Kezar Life Sciences | 59 | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| Andrew MBA | Shattuck Labs | 40 | |
| Brian Varnum | Armata Pharmaceuticals | 64 | |
| Duane BA | Armata Pharmaceuticals | 74 | |
| Brigit Riley | Adverum Biotechnologies | 46 | |
Management Performance
| Return On Equity | -1.0 | |||
| Return On Asset | -0.42 |
Frequency Therapeutics Leadership Team
Elected by the shareholders, the Frequency Therapeutics' board of directors comprises two types of representatives: Frequency Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Frequency. The board's role is to monitor Frequency Therapeutics' management team and ensure that shareholders' interests are well served. Frequency Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Frequency Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| John LaMattina, Advisor Board | ||
| David Lucchino, President, CoFounder | ||
| James Abely, Associate Sec | ||
| Christopher Loose, CoFounder Officer | ||
| Jason Glashow, Sr Affairs | ||
| William MD, VP Medicine | ||
| Quentin McCubbin, Chief Officer | ||
| Wendy Arnold, Chief Officer | ||
| Carl LeBel, Chief Officer | ||
| Dana MD, Chief Officer |
Frequency Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Frequency Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0 | |||
| Return On Asset | -0.42 | |||
| Current Valuation | 512.86 M | |||
| Shares Outstanding | 36.52 M | |||
| Shares Owned By Insiders | 7.26 % | |||
| Shares Owned By Institutions | 14.12 % | |||
| Number Of Shares Shorted | 365.89 K | |||
| Price To Earning | (7.43) X | |||
| Price To Book | 0.91 X | |||
| Price To Sales | 7.50 X |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Frequency Stock
If you are still planning to invest in Frequency Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Frequency Therapeutics' history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |